Health

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...
Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...
GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...
AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...
ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...
AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...
GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...
GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...
AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...
GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...
GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...
GSK plc announces strong financial results, with sales and profits driven by broad-based performance and COVID-19 vaccine sales...
Haleon plc has entered into a binding agreement to sell the ChapStick brand to Suave Brands Company, generating $430 million in cash proceeds...
Search

Funds

Financial Services

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...
Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...
GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...
AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...
ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...
AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...
GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...
GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...
AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...
GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...
GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...
GSK plc announces strong financial results, with sales and profits driven by broad-based performance and COVID-19 vaccine sales...
Haleon plc has entered into a binding agreement to sell the ChapStick brand to Suave Brands Company, generating $430 million in cash proceeds...
Search

Funds

Health

FTSE 100

Funds